Atrial fibrillation. Current recommendations for diagnosis and treatment

被引:1
作者
Kirchhof, P. [1 ,2 ,3 ,4 ]
机构
[1] Univ Birmingham, Inst Biomed Res, Ctr Cardiovasc Sci, Birmingham B15 2TT, W Midlands, England
[2] SWBH NHS Trust, Birmingham B15 2TT, W Midlands, England
[3] Univ Klinikum Munster, Munster, Germany
[4] Kompetenznetz Vorhofflimmern, Munster, Germany
来源
INTERNIST | 2013年 / 54卷 / 05期
关键词
Atrial fibrillation; Hemorrhage; Stroke; Catheter ablation; Cardioversion; Antiarrhythmic drugs; EXTERNAL CARDIOVERSION; FOLLOW-UP; AMIODARONE; MECHANISMS; MANAGEMENT; WARFARIN; TRIAL; TERM;
D O I
10.1007/s00108-013-3271-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) is by far the most common arrhythmia. It occurs more often with increasing age. Patients with AF almost always require oral anticoagulants and a rate-control treatment. In addition, other cardiovascular diseases must also be carefully treated in order to reduce the risks of cardiovascular complications from AF. Most patients profit from rate-control treatment with drugs that slow the conduction of the electrical impulse through the AV node. The aim is a resting heart rate of 100-110/min. If patients suffer from AF whilst on optimal rate control therapy, rhythm-control treatment with antiarrhythmic drugs, cardioversion or catheter ablation is indicated. The choice of the rhythm-control therapy should be made based on safety considerations. Whether achieving sinus rhythm beyond improvement of symptoms improves the prognosis of AF is tested in ongoing trials.
引用
收藏
页码:583 / 593
页数:11
相关论文
共 50 条
  • [1] Anticoagulation in atrial fibrillation Current evidence and guideline recommendations
    Erath, J. W.
    Hohnloser, S. H.
    HERZ, 2018, 43 (01) : 2 - 10
  • [2] Advances in the treatment of atrial fibrillation
    Capucci, Alessandro
    Compagnucci, Paolo
    GIORNALE ITALIANO DI CARDIOLOGIA, 2021, 22 (09) : 689 - 696
  • [3] New Insights in the Treatment of Atrial Fibrillation
    Meyer, C.
    Puererfellner, H.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 (06) : 257 - 260
  • [4] New Oral Anticoagulants During Catheter Ablation of Atrial Fibrillation. Experience With Rivaroxaban
    Kazakov, A. I.
    Yashin, S. M.
    Lyan, E. V.
    Ayrapetyan, A. V.
    KARDIOLOGIYA, 2015, 55 (08) : 30 - +
  • [5] Interventional treatment for paroxysmal atrial fibrillation. Which is the optimal ablation approach?
    Sultan, A.
    Lueker, J.
    Plenge, T.
    Steven, D.
    HERZ, 2015, 40 (01) : 25 - 30
  • [6] 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Summary of the document prepared by the Czech Society of Cardiology
    Fiala, Martin
    Haman, Ludek
    Cihak, Robert
    COR ET VASA, 2021, 63 (02) : 135 - 161
  • [7] Perioperative atrial fibrillation. Diagnosis with underestimated relevance
    Adamowicz, Sebastian
    Kilger, Erich
    Klarwein, Raphael
    ANAESTHESIOLOGIE, 2024, 73 (02): : 133 - 144
  • [8] New antiarrhythmic drug for the treatment of atrial fibrillation. Study data, clinical guidelines, regulatory agency recommendations
    Martsevich, S. Yu.
    Lukina, Yu. V.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2011, 7 (06) : 770 - 774
  • [9] Anticoagulation for atrial fibrillation. The future has begun
    Moser, M.
    Bode, C.
    INTERNIST, 2012, 53 (01): : 30 - 35
  • [10] Therapeutic management of non-valvular atrial fibrillation. Update 2013
    Bode, K.
    Sommer, P.
    Bollmann, A.
    Hindricks, G.
    HERZ, 2013, 38 (07) : 743 - 755